HOME >> MEDICINE >> NEWS
Where do new therapies work best?

An observational study to investigate how new therapies for rheumatic diseases perform across different conditions has revealed that they may be more successful in certain conditions. The data is presented today at the Annual European Congress of Rheumatology in Amsterdam, the Netherlands. An increasing proportion of patients with rheumatic conditions such as ankylosing spondylitis (AS), psoriatic arthritis (PsA) and rheumatoid arthritis (RA) now receive anti-TNF treatment a newer group of drugs which are used to reduce inflammation and manage disease activity*. Study lead Dr Marte Heiberg, of the Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, told delegates: "Many studies have focused on efficacy of these drugs, however less is known about comparative real life performance of these drugs across different diagnostic groups".

The study was conducted across 5 Norwegian Rheumatology Departments and included 796 RA patients, 162 PsA patients and 211 patients with a diagnosis of AS. All patients were on an anti-TNF treatment regimen of infliximab, etanercept or adalimumab +/- methotrexate (MTX). The primary outcome was the number of patients still on therapy at one year known as the adherence to therapy. RA was used as the reference group and within each diagnostic group the adherence to anti-TNF monotherapy versus TNF+MTX was compared.

The relative risk for withdrawal from TNF+MTX versus anti-TNF monotherapy was 0.54 for RA patients, 0.49 for PsA patients and 0.83 for AS patients, demonstrating that combination treatment strategy of anti-TNF+MTX worked better than anti-TNF monotherapy in patients with RA and PsA. Although the crude one-year overall drug adherence rates for anti-TNF therapy were superior in patients with PsA and AS compared to RA, after adjusting for age, gender and concomitant MTX, the adherence to anti-TNF treatment were similar in patients with RA and PsA whereas the adherence to anti-TNF treatment was superior in patients
'"/>

Contact: Mia Gannedahl
mia_gannedahl@uk.cohnwolfe.com
44-207-331-2325
European League Against Rheumatism
22-Jun-2006


Page: 1 2

Related medicine news :

1. Wheres the beef? Not enough of it is on elders plates, muscle-metabolism study suggests
2. Where is the most dangerous place to travel over the holiday?
3. Where should I have my outpatient surgery?
4. Where are medical graduates practising and why?
5. Where the brain organizes actions
6. Where we change our mind
7. Where your brain wires itself to like (name your favorite brand)
8. Where lifes memories are stored
9. Future therapies for stroke may block cell death
10. Antifolate therapies found effective against certain type of malaria
11. Combined molecular-targeted and hormonal therapies offer promise in treating ovarian cancer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Where new therapies work best

(Date:5/29/2015)... (PRWEB) May 29, 2015 Red Hot ... the newest Red Hot & Blue restaurant at 525 New ... Thursday, May 7, 2015. “The Red Hot & Blue Restaurant ... 18 years, but we have moved to a new location ... in the middle of all the activities on the Promenade–with ...
(Date:5/29/2015)... The Healthcare Delivery Institute at HORNE ... Training Program (ATP) in Healthcare Delivery Improvement. The ... health care organization ranging from clinicians to CFOs, ... quality improvement in the health care environment. The ... internationally recognized Advanced Training Program at Intermountain Healthcare. ...
(Date:5/29/2015)... Inspire Nexus, a new social network officially launching ... many life coaches have asked, "How do I find ... to become a credentialed Coach?" , Many Life and ... long. Inspire Nexus, a social network for Coaches provides ... have experience coaching a certain number of hours, qualify ...
(Date:5/29/2015)... York, NY (PRWEB) May 29, 2015 ... wellness, as well as a number of specific concerns ... care, stigma reduction and mental health in the workplace. ... about mental health. The campaign also brings special focus ... those individuals to speak up and seek help from ...
(Date:5/29/2015)... TX (PRWEB) May 29, 2015 ... 2015” provides comprehensive information on the therapeutic development ... types of muscles in the body, leading to ... R&D pipelines by identifying new targets and MOAs ... on H1 2015 pipeline review of Axillary Hyperhidrosis ...
Breaking Medicine News(10 mins):Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 2Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 3Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 4Health News:HORNE LLP’s Healthcare Delivery Institute Graduates Class from the Advanced Training Program 2Health News:Mediaplanet Brings Activism to Those Living with Mental Illness in Bew “Mental Health Awareness” Campaign 2Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4
(Date:5/29/2015)... LifeNet Health plans to enlarge its workforce ... more than 160 people. The organization,s growth ... innovative bio-implants, which are being made more widely available ... It also is a reflection of the region,s growing ... and success of LifeNet Health is a great example ...
(Date:5/29/2015)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the ... commercializing proven cancer therapies in new orphan drug ... American Association of Cancer Research (AACR) Advances in ... for its lead product candidate VAL-083 ...
(Date:5/29/2015)... Educating the community continues to be ... Advancement of Wound Care (AAWC), which was incorporated ... corporate partners, the Association provides medical professionals with ... website at http://aawconline.org/education-for-the-generalist/ . The portal is ... to various CME/CEU educational programs. This education is ...
Breaking Medicine Technology:LifeNet Health to add more than 160 jobs in 2015 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5The Association for the Advancement of Wound Care Educates the Public 2
Cached News: